IP Library Granted Patent US 8,318,485
Granted Patent B2
US 8,318,485 · App. 12/036,424 · Granted Nov 27, 2012

Stem cell therapy for the treatment of diabetic retinopathy and diabetic optic neuropathy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,318,485
App. No.
12/036,424
Granted
Nov 27, 2012
Kind
B2
Abstract

The invention comprises methods and stem cell compositions for the treatment of diabetic retinopathy and other degenerative diseases of the eye. The invention is practiced in two stages with the first stage comprising the administration of neural stem cells to the eye, and the second stage comprising the administration of mesenchymal cells intravenously.

Claims (18)

1. A method for treating diabetic retinopathy in a subject comprising:

administering ectodermal cells to the retinal tissue of said subject; and

intravenously administering mesenchymal cells to said subject;

wherein said method treats said diabetic retinopathy.

2. The method of claim 1 , wherein said ectodermal cells are obtained from one or a combination of fetal neural tissue, adult neural tissue, and embryonic tissue.

3. The method of claim 1 , wherein said mesenchymal cells are obtained from postnatal tissue.

4. The method of claim 1 , wherein said mesenchymal cells are obtained from bone marrow.

5. The method of claim 1 , wherein said mesenchymal cells are obtained from umbilical cord blood, placenta or combinations thereof.

6. The method of claim 1 , wherein said ectodermal cells are injected by one or more of the administration routes selected from retrobulbarly, intravitreously, and subchoroidally.

7. A method for treating diabetic retinopathy in a subject comprising:

administering ectodermal cells to the eye of said subject; and

intravenously administering mesenchymal cells to said subject;

wherein said method treats said diabetic retinopathy.

8. The method of claim 7 , wherein said ectodermal cells are administered to the retinal tissue of said eye.

9. The method of claim 7 , wherein said ectodermal cells are obtained from one or a combination of fetal neural tissue, adult neural tissue, and embryonic tissue.

10. The method of claim 7 , wherein said mesenchymal cells are obtained from bone marrow.

11. The method of claim 7 , wherein said ectodermal cells are injected by one or more of the administration routes selected from retrobulbarly, intravitreously, and subchoroidally.

12. The method of claim 7 , wherein said ectodermal cells and/or said mesenchymal cells are derived from a cloned cell population.

Assignments (2)
SECURITY INTEREST Recorded Dec 15, 2022
From: STEMEDICA CELL TECHNOLOGIES, INC
To: KINSELLA CONSULTING & INVESTMENTS, LLC
Reel/Frame 062137/0080 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2018
From: GAVRILOVA, NATALIA; SABURINA, IRINA; MIRONOV, ILYA
To: STEMEDICA CELL TECHNOLOGIES, INC
Reel/Frame 046507/0831 →
Continuity (1)
Related Publication 20090214485A1 · Aug 27, 2009